Introduction
The discovery of an ovel drug is usually am ultiphase process, with one of the keys teps being the identification of active molecules that bind to ab io-macromolecular target. Several methods are available to medicinalc hemists for early drug hit discovery, including high-throughput screening (HTS), fragment-based and computer-assisted drug discovery. In recent years, the screening of DNA-encoded chemical libraries (DECLs) has increasingly complemented established early hit discovery methods. [1] DECLs are assemblies of combinatorial small molecules, each linked to au nique DNA sequence that makes its unambiguous identification possible. DNA encoding renders these small molecule libraries compatible with simple affinity selection protocols inspired by those used in phage display and relatedt echnologies. In fact, DNA-encoded libraries encompass ab road spectrumo fd iscovery technologies, including phage display,m RNAd isplay,a nd SELEX, although this minireview focuses only on small molecule DECLs. Typically, aD ECL is incubated with an immobilized protein of interest, and the weak binders are subsequently removed by washing steps (Figure 1 ). Amplifying the DNA tags of the surface-retained small-molecule conjugatesa nd subsequenth ighthroughput DNA sequencing deconvolute the structures of high affinity target binders. This rapid and inexpensive screening protocol requires only standard laboratory equipment and is compatible with ultra-largel ibraries. The speed and simplicity of this approachc omparef avorably to widely used HTS, which individuallyt ests each candidate compound in as eparate well by using suitable bioassays.
DNA-Encoded Libraries in Academia and Industry
The technological advancements of DECLs in recent years have established DECL screening as ar outine methodf or hit discovery.T he size and chemical diversity of these libraries are constantlye xpanding. Furthermore, the number of reported DECL screening hits is growingr apidly, and as ubstantial fraction of recentd iscovery compoundsh ave physicochemical properties compliant with parameters that predict peroral bioavailability. For example, an inhibitor of soluble epoxide hydrolase identified from aD ECL screen [2] entered phase Ic linical trials as a potentiald rug for cardiovascular and respiratory conditions. [3] Similarly,as eries of inhibitors of receptor-interacting protein 1 (RIP1) kinase have shown favorable potencya nd pharmacokineticp roperties for furtherevaluation in clinicalstudies. [4] The success of DECL screening as ap rospective drug discovery technology builds on years of complementary academic and industrial research efforts. This minireview provides an academic perspective on the developmenta nd possible future directions of DECLs. We summarize key advancements originating from academia-based researchers and outline potential future opportunities and challenges in this field. An excellent article by Arico-Muendel describing DECL activities at GlaxoSmithKline offers ap erspective from ap harmaceutical industry standpoint. [5] Severalreviewsare availabletor eaders interested in am ore comprehensive description and analysis of concepts and technical aspects of DECLs. [1, 6] We examined DECL-relevant literature to evaluate the contributions of academia-and industry-based research (Figure2)t o this field. For this purpose, we categorized ar epresentative set of 121 DECL-related peer-reviewed publications (this analysis does not include patents) into three types of articles based on subject matter:1 )Development/advancement:d escribes novel or improved methods used in DECL preparation and screening. Such articles include manuscriptst hat describe on-DNA compounds ynthesis, encoding, and DECL screening techniques without the preparation or use of an encoded library.2 )Synthesis and proof-of-principle screening:d escribes the prepara-DNA-encoded chemical libraries (DECLs) are pools of DNAtagged small molecules that enablef acile screening and identification of bio-macromolecule binders. The successful development of DECLs has led to their increasingly important role in drugd evelopment, and screening hits have enteredc linical trials. In this review,w es ummarize the development and currently active research areas of DECLs with af ocus on contributions from groups at academic institutes. We furtherl ook at opportunities and future directions of DECL research in medicinal chemistry and chemical biology based on the symbiotic relationship between academia and industry.C hallenges associated with the application of DECLs in academic drugd iscovery are furtherd iscussed. tion of encoded libraries and hit discovery demonstrationstudies. In these reports, screening compounds were not further optimized or studied beyond hit validation. 3) Application:d escribes the implementation of encoded libraries for actualh it discoverye fforts. These studies involved extensive hit-to-lead efforts or thorough biochemical and preclinical evaluations. Articles that follow up on initial DECL-derived hits also fall into this category.A rticles were further assigned as academia-or industry-derived based on the affiliation of the principle investigator or the origin of the DECLs.
This analysisr eveals severali mportantt rends, even though it was not comprehensive, and category assignments werec ertainly subjective (Figure2) . First, the number of DECL-related publications increased considerably in recent years (from an average of 4.6 articles per year between 2000-2013 to 19 articles per year for 2014-2016), especially with regard to articles from industry.Second,t he field benefited from substantial contributionsf rom educational institutes and companies,w ith the majority of publications before 2010originating from academic groups.T hird, the relative distribution of the categories was distinctly different for academia compared to industry.T echnology development and advancement wasaprimary focuso f academic research,a nd only af ew reports described academia-derivedD ECLs in discovery efforts for drug leads or chemical probes. In contrast, hit discovery was the primary subject of industry-contributed DECL publications. This dissymmetry in research focus reflects the differences in missions and resources of academic and industrial research and illustrates their symbiotic relationship in this area.
Technical Advancements

Librarysynthesis and encoding methods
Many key concepts and methods for the preparation and application of DECLs were initially described by nonprofit research groups. Lerner and Brenner introduced the concept of encoding molecules by amplifiable DNA barcodes in 1992. [7] Shortly thereafter,r esearchers at Affymax and Scripps putt his approachinto practicebyg enerating DNA-encoded one-beadone-compound libraries.
[8] Despite the successful proof-of-principle, DECLsf ailed to gain broader attention at the time because of technical and operational challenges. The invention of efficient library preparation methodsr einitiated the interest in the DECL field in the early 2000s. Severalg roups independently pioneered approaches for the synthesis of soluble DNAtagged small-molecule libraries. The Liu and Harbury groups invented protocols based on DNA-templated multistep synthesis [9] and code-specific routing, [10] respectively,a sp aradigms for DECL preparation. TheN eri group proposed linking chemical diversity to DNA readoutsb yc ombining potential drug fragments through DNA hybridization. [11] Winssinger et al. described PNA-encodedm olecules (we use the term DECL generically for all types of encoded libraries) that could be assembled on oligonucleotide microarrays. [12] These approaches remain in active use forlibrary generation and implementation, and several spin-offc ompaniesh ave been founded based on these concepts (Ensemble Discovery,P hilochem, Dice Molecules).
Although provens trategies for DECL generationa re available, the invention of novel synthesis/encoding methods remains an active research area. In particular, ap ool-and-split DECL synthesis approach relyingo ni terative compound synthesis and encoding steps is now widely used forD ECL preparation. [13] Selectede xamples of more recentD ECL assembly protocols include encoding of self-assembled fragment combinations, [14] autonomous molecular assembly, [15] PNA-encoded librariesl inked to amplifiable DNA barcodes, [16] and novel types of one-bead-one-compound libraries. [17] Technologies developed in industry complemented these research efforts, as exemplified by the invention of the yoctoliter reactor [18] and chemicale ncoding. [19] To access ultra-large DNA-encoded libra- ries of chemically diverse compounds, more efficient, robust and economicalencoding strategies continue to be desired.
Reactionsfor library synthesis
The main challenge with DECL assembly is the high-yielding synthesis of chemically diversec ompounds on DNA. Nucleic acids are polyfunctional molecules, and the number of chemical reactions that are compatible with DNA is limited, which severelyr estrictst he accessible chemical space. Consequently, libraries reported to date have generally relied on ar elatively small set of chemical transformations for their preparation. Reactions of amines with electrophiles (e.g.,a mide bond formation, reductivea mination, nucleophilic aromatic substitution) have been particularly ubiquitous in DECL synthesis. [1] The synthesis of aD ECL involving aD iels-Alder cycloaddition step was an early example of efforts to expandt he reaction scope of DECL synthesis. [20] Av ariety of DNA-compatible and diversitygenerating reactions emerged in recent years and significantly expandedt he chemists' toolbox. [21] Of special appeal are reactions that generateh eterocycles [21a] andt ransition-metal-catalyzed cross-couplingr eactions (e.g.,S uzuki-Miyaura coupling).
[22] The continued need to expanding the reactions for DECL preparation opens great opportunities for organic chemists and might lead to collaborations between academic researchersa nd companies interested in DECLs. Thed evelopment of DNA-compatibler eactions that can assembles ets of buildingb locks in diverse arrangements remainsaparticular challenge. In addition to increasing the number of DNA-compatible reactions, it is also mandatory to thoroughlye valuate existing chemical transformations in the context of DNA. Preparation of DECLs requires large sets of structurally diverse buildingb locks to react cleanly and in high yield with DNA-appended molecules. Even for widely used DNA conjugation reactions,y ields are often strongly dependent on the substrates. For example, although amide bond formation, [23] SuzukiMiyaurac oupling, and reductiveamination [22a] are high-yielding reactions in general,t hey can fail for ac onsiderable fraction of buildingb locks. In the case of amide bond formation,the reaction is especially challenging for DNA-appended acyclics econdary amines and aromatic amines. [23a] Studies that systematically analyze the coupling efficiency of diverse building blocks for reportedo n-DNA reactions would be important for future DECL synthesis. The development of post-synthesis clean-up methods [24] would also be of value. As tudy by Malonea nd Paegel is an illustrative example of how academic research can advance our understanding of synthesis methodsf or DECLs. [25] These authors critically assessed the impact of diverse reportedD NA-modification reactionc onditions on the integrity of the DNA-encoded information. [25] It was found that severalr eactions used for DECL synthesis were accompanied by substantial DNA damage and should only be used with caution for DECL preparation. Even Cu I -catalyzed azide-alkyne cycloaddition-ar eactionr egarded as highly biocompatible-can be problematic in terms of DNA integrity. [26] Such criticals tudies that present potentialp itfalls in DECL synthesis are of great value to the scientific community.
Screening protocols
In addition to researcha imed at improving methods forl ibrary synthesis, there are continued efforts to advance screening protocols. [27] The main challenge in the early years of DECL development was the identification of enriched sequences. In phaged isplay,o nly as mall number of phages are typically sequenced for hit identification,w hich results in undersampling of the libraries. As ac onsequence, the phage population must consist nearly exclusively of bindersw ith high target affinity for hit identification, and several screening-amplification cycles are generallyr equired to achieve this goal. However,i terative screening/amplification protocols were challenging to reproduce with DNA-encoded small molecule libraries, because methodst ot ranslate aD NA code into al ow-weighto rganic compound were lacking. The use of DNA-templated synthesis [9, 28] and DNA-based routing [10b] for DECL preparation aimed at enabling post-selection library amplification, which should allow repeat cycles of compound synthesis and screening. Wrenn et al. successfully demonstrated am ulti-selection-round sampling of aD NA-encoded library to discover peptoid-based SH3 domain ligands. [29] DNA microarrays have been used as an alternative readout tool for DECLs. The screening of DECLs is performed in solution, and the bound ligands hybridize to the corresponding microarray spot and can be identified by using af luorescent readout. and Melkko et al. used this approacht oa nalyze screening results of encoded self-assembled libraries. [11] The direct and rapid readout of microarrays makes them highly useful for screening DECLs of moderate size (< 10 5 encoded compounds), and this approachh as been successfully appliedt o the discovery of affinity binders [16b, 30] and enzyme substrates.
[31]
However,m icroarrays are unsuitable for libraries containingb illions of compounds, as have been described recently. [32] The advent of high-throughput DNA sequencing transformed how DECLs are screened. With this technology,i t becamep ossible to analyze sequence enrichment even after as ingle round of affinity selection, [13] and the development of approaches to amplify post-selection libraries becameu nnecessary.
In the most widely used DECL screening protocol, al ibrary is incubated with target protein immobilized on as olid support, which allows unboundl igands to be washed away (Figure 1B) . [33] The purifiedt arget proteinsc an be linked to agarose [31] or magnetic beads [33, 34] as as creening matrix. Though provene ffective in multipl studies, this screening protocol has several potential limitations;f or example, interactions of the DECL with the solid support and loss of native protein folding upon immobilization might influences creening outcomes.
Several research groups have developed alternative screening protocols.T he possibility of using gel [31a, 35] or kinetic capillary electrophoresis [36] has been evaluated. Furthermore, solution-based screening methods with photo-crosslinkers have been identified to facilitate affinity selection. [37, 38] DNA-encoded dynamic combinatorial libraries were furtheri ntroduced to in- ChemBioChem 2017, 18,829 -836 www.chembiochem.org crease the number of protein bound ligandsi nt he library. [39, 40] This approach relies on ad ual-pharmacophore library design with au niversal DNA hybridization region that is too short to form as table duplex at room temperature. Once the target protein binds to the DNA-appended fragments, the associated DNA duplexes are also stabilized. Hence, the formation of protein-ligand complexes re-equilibrate the library and generate more protein-binding combinations, which increases sequence counts in the selection. [40] Conventional DECL screening protocols require purified protein at high concentrations. This limitation leads to the exploration of alternative screening methods that use cell lysates and whole cells. Liu and co-workersi ntroduced interaction-dependentP CR, [41] which they later modified to identify ligands with aD ECL directly in cell lysates.
[42] Li et al. described exonuclease-protected selection, which in combination with aphotocrosslinking tag, enabled the identification of protein ligands in spiked cell lysate.
[37b]
For the first time, the Bradley group explored the possibility of screening aP NA-encodedp eptidel ibrary directly on human cells and successfully identified new surfacer eceptor ligands.
[16a, 43] Am ore comprehensive study by researchers at GSK concerning on-cellD ECL screening recently demonstratedt he generality of this approach and led to the identification of several high-affinity NK3 tachikinin receptor ligands. [44] The large number of membrane-associated drug targets makes this approachh ighly valuable, and there is potentialf or further improvement in this direction.
Applications beyonddrug hit discovery
DECL-related research thus far has focused on developing DECLs as tools for earlyd rug hit discovery. With increasing maturity of this technology,i dentifying alternative uses for DECLs in chemical biologyo ffers great opportunities for the future.
[6b]
One potentiala pplicationo fD ECLs is to profile the substrate space of enzymes. PNA-encodedl ibraries of covalentp rotease inhibitors have been developed to assessp rotein function. [12b] With this approach, it was possible to identify caspase activities in crude cell lysates with as mall set of PNA-linked peptides. For example, such libraries enabledt he profiling of protease activity in dust mites. [31a] Novel activity-basedp robes have recently been proposed that can be applied to different enzyme families, including proteases, protein kinases, and transferases. [45] Such probese nabled the positives electiono f enzyme substrates and could be applied to measure protein activity based on aqPCR readout. [45, 46] The development of libraries for the identification of covalent enzyme inhibitors is also of interest. PNA-encoded libraries of activity-based irreversible inhibitors were reported years ago for protease substrate identification. [47] Recently,t hese efforts were expanded to targetc ysteine residues outside the enzymatic actives ite. Libraries containing Michael acceptors as buildingb locks in the DECL provided covalentb inders for bromodomains [48] and two kinases (MEK2 and ERBB2). [49] DECLs have also been proposed as tools for reactiond iscovery.
[50] Al ibrary was built on am icroarray chip that allowed the scientists to rapidly screenr eactionc onditions by using fluorescencet o signalb ond formation.
DECL is not limited to smallm olecules;r esearchers have recognized the potential of DECLs for barcoding bio-macromolecules for biological applications. The Muir lab used aD NA-encoded nucleosome libraryt or eveal interactions between chromatic-associated factors and histone post-translationalm odification patterns. [51] Heath and co-workersd escribed the use of DNA-encoded antibodyl ibraries as am ethodf or cell sorting and protein/nucleic acid detection, [52] which they expanded to analyze protein in blood samples on am icrofluidic chip. [53] These activities at the interface of DECLs and conventionald isplay technology open opportunities for multiple future applications in the biological sciences.
Encoded Libraries in Academic Drug Discovery
Large pharmaceutical companies increasingly use DECLsi n routine hit discovery campaigns, and the first leads originating from DECL screensh ave enteredc linical trials. [3] The implementation of DECLs in academic drug discovery has so far been limited, even thoughm any key concepts and methodologies were developed at academic institutions( Figure 2) ;t he characteristics of DECLs should, in principle,h old particular benefits for scientists in such environments. Relative to classic HTS libraries, DECLsa re inexpensive to prepare; [54] furthermore, DECL screening is rapid, economical, and requires only standard laboratory infrastructure. DECLs obviatet he need for tedious screening assay development and advanced robotics.
One factor that might partially explaint he hesitant adaptation of DECLs at universitiesi st hat HTS libraries are commercially accessible, whereas the availability of DECLs remains limited. Commercial suppliers can offer HTS libraries to multiple users at af raction of the costs of initial libraryp reparation and in this way mitigate the cost disadvantage of preparing HTS librariesr elative to DECLs. DECLs, in contrast,a re typically prepared by specialized research groups in house.A na dditional challenge with DECLs is that costs for library preparation occur up fronta nd only amortizeo ver an extended time period. Large sets of building blocksa nd oligonucleotides need to be acquired before library synthesis can begin. Tedious reactivity tests and optimization studies might also be necessaryb efore library preparation. Although several investigators have reported ab road distribution of reaction yields for diverse sets of buildingblocks, [22a, 23] the reactivity of the actual structures generally remains undisclosed and needs to be redetermined by each group. Development and validation of screening protocols, softwaref or sequencing analysis, and high-quality target proteins are also neededf or DECL research. These combined factors constitute significant hurdlesf or researchers to enter this field.
Despite these challenges, several groups have demonstrated the possibility of performing hit discovery with DECLs generated at universities. Selected successful studies include am acrocyclic inhibitor of insulin-degrading enzyme [55] (a target for which conventionale fforts were unsuccessful), inhibitors of ChemBioChem 2017, 18,829 -836 www.chembiochem.org tankyrase 1a nd PARP1w ith drug-like features, [34, 56] and isoform-selective inhibitors of protein phosphatase PTP1B (Scheme1). [57] As the number of libraries and their size continue to grow,t he frequency of discovered hits will certainly increase.H owever,t he screening productivity of current libraries in academia is suboptimal, even though reliable statistical data is unavailable. For example, al ibrary of 13 824 encoded macrocycles provided successful hits for Src kinase, whereas suitable screening hits werea bsent for the majority of targets in a panel of 36 biomedically relevant proteins. [58] Similarly,a30 000 compound DECL provided binders of interleukin 2, butn oh its were reported for the other 25 targets screened in this study. [59] Recent publications from DECL groups in the pharmaceutical industry provide useful guidelines on the requirementsf or consistents creening success. Generally,s uch DECL screensi nvolve pools of libraries rather than individual DECLs. Eidam and Satz recently analyzed screening productivityo faset of 16 chemically diverse DECLs for two undisclosed protein targets. [32] Multiple clusters of structurally relatedh it compounds were identified. Importantly,s everal of the screened libraries lacked enrichment patterns suggestive of hits. [32] Similarly, Arico-Muendel et al. identified inhibitors for hepatitis Cv irus protein NSB4, but most DECLs in the library pool failed to provide hits. [60] In conclusion, severall ibraries with diverse chemotypes might be required to ensure the compound-target complementarity necessary for reliable hit discovery.
In addition to the ability to screen several libraries in parallel, large pharmaceutical companies have DECLs that are considerably larger in terms of overall size andn umber of building blocks used per synthesis cycle than their academic counterparts ( Figure 3 ). The libraries reported by Eidam andS atze ncompassed9 74 to 9539 distinct buildingb locks; [32] in contrast, DECLs reported to date by academic groups consistently contained < 1000 discrete building blocks. [1] This difference is apparenti nF igure 3, in which industry-and academia-derived DECLs separate into two distinct populations according to size. There are likely ongoing efforts to generate more and larger librariest oenhance DECL screening success at academic institutions, and it will be interesting to see how these steps further screening success.
Differences in accessible resources is one factor responsible for the discrepancy in library size between academia andi ndustry.T oi llustrate this point, it is sufficientt oa nalyze the costs associated with the acquisition of buildingb locks. A hypothetical academic library prepared in two synthesis cycles by using 250 250 buildingb locks would contain 62 500 compound combinations andr equire at otal of 500 building blocks.A ssuming an average cost of $50 per building block, the overall costs for chemical fragments would be approximately $25 000. Al ibrary with the same overall structure but with 2500 2500 building blocks (6 250 000 encoded compounds) would require chemicals valuingaround$1000 000 assuming ana verage cost of $200 for the building blocks (building blocks becomem ore expensive for larger libraries because of limited availability). Large pharmaceutical companies often already have extensive sets of buildingblocks from prior library synthesis activities and the resources to follow multiple targets, therebyd istributing the costs of building al ibrary.B ased on our postulation that as ingle library would likelyb ei nsufficient to generate consistent screening success for diverse targets, an entire platform of large libraries would need to be prepared. Even though buildingb locks and oligonucleotides can be used for the synthesis of several libraries, the resources necessary for such library pools are beyond the means of most research groups at universities.
One approach to overcomet he challenge of limited resources is to restrict hit discoveryt os pecific protein target families. In this way,i ti sp ossible to generate structurally focused DECLs that might afford reliable screening productivity at a fractiono ft he cost of one-fit-all platforms necessary for univer- [57] by enriching the building blocks with putative phosphatase-binding fragments combined with generic building blocks. This library affordedi nhibitors for PTP1B (K i = 0.25 mm)a nd TCPTP (K i = 0.8 mm), despite its modests ize of 10 4 members. [57] Similarly,l ibrariesb ased on benzodiazepine and pyrazolopyrimidine scaffolds wererecently published. [61] In addition to offeringafavorable return on investment, this approachopens the possibility for an entirely new drug discovery paradigm. The high expenses associated with conventional drug hitdiscoverym ethods requireastrongm otivation to perform hit identification for ap articulart arget. As ar esult, most hit discovery efforts are biasedt owards as mall subset of alleged high-value targets, [62] and the majority of potential proteins remain unstudied, even though many might have disease-relevant functions. In contrast, the minimal costs of DECL screening enable the interrogation of large numbers of target proteins.This approach makes it possible to screenentire families of proteins in parallel by using limited sets of structurally focusedl ibraries. Identified hits could then be evaluated in phenotypics tudies, providing first-timei nformation on target function. Parallels creening might also enable researchers to identify isotype-specific inhibitors, [63] which is cumbersome with conventionalapproaches.
Once DECL preparation is complete, it is possible to screen al ibrary for an ear-limitlessn umber of targets at low costs (mostly DNA sequencingc osts,w hich will likely continue to fall in the future). An entire DECL fits into as ingle microcentrifuge tube, which is ideal fors hipping and storage. Simple screening protocols based on pipette tips or cartridge-based methods have been described, and advanced infrastructure is unnecessary.T hese properties enablethe decentralizationo fh it discovery efforts with DECLs. It would be possible for groups specializing in DECL synthesis to make libraries available to end users, who would perform the screening steps and return the postselections amples for sequencing and data analysis. Alternatively,r esearchers could submitt heir target proteins of interest (micrograms are sufficient) to ac ore screening lab for hit discovery.I nt his way,l ibrariesw ould find widespread application and justify the significant upfront costs associated with their synthesis. Such an arrangementw ould have the potential to truly transform drug discoveryr esearch at academic institutions. The developments in this field over the last two decades have provided the necessary knowledgef or the implementation of such al ibrary sharing strategy.
Summary and Outlook
DECLs are playing an increasingly important role in both drug discoverya nd basic research. The ability to barcode unnatural molecules by using DNA has allowed researchers to sort and screen libraries and enable the identification of compounds withoutextensive knowledge of the target. Academic researchers have made important contributions to the development of DECLs in the form of reaction development/evaluation, [23a] library synthesis/encodingm ethods, [14] and screening protocols [33] since the 1990s. Implementation of academia-derived libraries in drug discoveryr emains limited to date beyond proof-of-principle discoverys tudies. Pharmaceutical companies have demonstrated that screening DECLs can routinely afford screening hits, [64] and ar ecent paper published during the review process of this minireview further demonstrated the potentialo fD ECL in drug discoverye fforts. [65] It is hoped that the rapid advancement of this technologyw ill lead to broader applicability in academic drug hit discovery as well. Conclusively, DECLs have the potential to become at ransformativet echnology for drug development and chemical biology research. 
